Repurposed drug – Page 5 – Communicable Diseases Research

A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019

Review

Published on 2021-09-182022-10-30
Journal: Journal of Personalized Medicine [Category] COVID-19,

Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells

인간 세포에서 SARS-CoV-2 복제를 늦추는 용도 변경 약물의 발견

Research Article

Published on 2021-09-092022-09-10
Journal: PLoS Pathogens [Category] SARS, 바이오마커, 신약개발,

[키워드] addition amodiaquine atovaquone Author bedaquiline candidate cell types COVID COVID-19 COVID-19 vaccine COVID-19 vaccines drug Drug repurposing ebastine effective evaluated FDA-approved drugs help hepatocyte hepatocytes human cell human cells Immunity infected cells Infection kidney Liver damage luciferase LY2835219 manidipine measure nLuc panobinostat patients with COVID-19 performed Protein Proteinuria proximal tubule proximal tubule cell proximal tubule cells reduced replication Replication reported Repurposed drug Repurposed drugs required SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Screen Spike protein Support the disease the Spike Therapeutics treat treated Treatment utility Vero Cell Vero cells Viral Viral load virus virus replication Vitamin D3
[DOI] 10.1371/journal.ppat.1009840 PMC 바로가기 [Article Type] Research Article

Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics

Article

Published on 2021-09-082022-10-04
Journal: Scientific Reports [Category] SARS, 치료제,

Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study

SARS-COV-2 주 프로테아제를위한 용도로 인한 약물로서 HIV-1 프로테아제 억제제-임상 시험 약물의 가능성 : 분자 도킹, 분자 역학 및 결합 자유 에너지 시뮬레이션 연구

Article

Published on 2021-09-012022-08-31
Journal: Journal of biomolecular structure & dynamics [Category] SARS, 신약개발, 치료제,

[키워드] active site Amino acid amino acids Antiviral bind binding binding free energy binding mechanism clinical trial complexes COVID-19 COVID-19 pandemic develop docking result docking results drug Drug repurposing enzyme form free energy Free energy calculations help HIV-1 HIV-1 protease clinical trial drugs in silico inhibitor inhibitors inhibitors of SARS-CoV-2 Initially Interaction intermolecular interaction intermolecular interactions key amino acid key amino acids M pro MD simulations molecular molecular basis molecular docking molecular dynamics overcome performed protease Repurposed drug Repurposed drugs RMSD RMSF SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 virus SARS-COV-2Mpro Scientific community strong interaction the SARS-CoV-2 the SARS-CoV-2 virus therapeutic agents TMC310911 Trial Wuhan Wuhan, China
[DOI] 10.1080/07391102.2020.1786459 PMC 바로가기 [Article Type] Article

Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study

COVID-19 용도 변경 약물을 Medicare 및 상업적으로 보험에 가입된 환자의 약물 요법에 가상으로 추가하여 약물 부작용 위험 평가: 약물 안전성 시뮬레이션 연구

Observational Study

Published on 2021-09-012022-09-11
Journal: Clinical and translational science [Category] MERS, 신약개발, 임상, 치료제,

[키워드] added addition ADE ADEs Adverse age Analysis approved Azithromycin baseline blueprint calculate caused Chloroquine clinical trials conducted coronavirus disease Coronavirus disease 2019 COVID-19 driven by drug drug interaction drug regimen drug regimens drugs event fexofenadine greater groups Health Health Insurance Hydroxychloroquine increase in increased risk indications Intervention Long Long QT syndrome Lopinavir Lopinavir/ritonavir median Medicare medication medication risk negative control Patient performed positive Repurposed drug Repurposed drugs risk Ritonavir subject terfenadine Treatment were used
[DOI] 10.1111/cts.13025 PMC 바로가기 [Article Type] Observational Study

A critical overview of computational approaches employed for COVID-19 drug discovery

COVID-19 약물 발견에 사용되는 컴퓨터 접근 방식에 대한 중요한 개요

Review

Published on 2021-08-212022-09-11
Journal: Chemical Society reviews [Category] MERS, SARS, 신약개발, 임상, 치료제,

A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses

Article

Published on 2021-08-182022-10-28
Journal: Viruses [Category] COVID-19, Fulltext, SARS, 조류인플루엔자,

[키워드] activity acute respiratory syndrome antiviral therapy caused clinical trials coronavirus Coronavirus replication demonstrated derivative drug candidate Efficiency examined frameshift frameshifting gene cluster identify in viral in vitro inhibit inhibitor inhibitors inhibitory effect interfere less MERS-CoV MERS-CoV-infected cells Middle East novel outbreak RdRP recent Repurposed drug respiratory syndrome coronavirus RNA RNA-dependent RNA polymerase RNAs SARS-CoV SARS-CoV-2 searched Shock shown small molecule suppresse therapeutic agent therapeutic efficacy translated translation viral propagation zoonotic coronaviruses
[DOI] 10.3390/v13081639 PMC 바로가기 [Article Type] Article

Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents

Research article

Published on 2021-08-012022-10-05
Journal: Medical Hypotheses [Category] SARS, 신약개발, 치료법, 치료제,

[키워드] acute COVID-19 acute respiratory syndrome ALF Ambulatory treatment Anti-infective Anti-inflammatory Anticoagulant Antiplatelet agent Antithrombotic Antiviral benefit Care clinical suspicion coronavirus Corticosteroid Corticosteroids COVID-19 Cytokine storm death deaths doctor early treatment elderly Elderly patient endothelial injury helping high-risk patient highest hospital Hospitalization Hydroxychloroquine Hypothesis illness Immunity implication In-hospital Infection initial initiated kidney LTF Lungs morbidity and mortality Mortality natural immunity nine nursing home outbreak outcome Patient patients Population positive post infection Prevent Probability provide pulmonary failure receive reduce reduced reduction in mortality regimen Repurposed drug risk robust SARS-CoV-2 SARS-COV-2 infection sequenced severity sick significantly Spread statistically significant Symptom the disease the patient therapeutic option therapy thrombosis Transmission treat Treatment viral replication with COVID-19 worsening
[DOI] 10.1016/j.mehy.2021.110622 [Article Type] Research article

Case Management of COVID-19 (Secondary Version)

Review Article: COVID-19

Published on 2021-07-092022-10-30
Journal: JMA Journal [Category] COVID-19,

[키워드] Anxiety clinical trials COVID-19 Dexamethasone disease disease severity drug therapy effective Efficacy evaluated example Healthcare system identify Laboratory management marker Medical resources Patient patient groups reduce Remdesivir Repurposed drug secondary selected severe cases severe disease severity Standard therapy Steroids Tocilizumab Version
[DOI] 10.31662/jmaj.2021-0036 PMC 바로가기 [Article Type] Review Article: COVID-19

Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review

COVID-19 관리에서 렘데시비르의 효능, 효과 및 안전성을 평가하는 임상 연구: 범위 검토

Review

Published on 2021-07-012022-09-11
Journal: British Journal of Clinical Pharmacology [Category] SARS, 치료제,

[키워드] accumulated accumulating acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events Adverse reaction Antiviral association clinical Clinical improvement clinical status clinical trial conducted control groups coronavirus COVID COVID 19 COVID-19 decreased mortality Effectiveness Efficacy Efficacy and safety Evidence expected GS 5734 hepatic impairment Hospitalized increased survival Intervention management Median recovery time observational studies observational study OVID Participants Patient patients patients with COVID-19 proportion quantitative synthesis randomized-controlled Recovery time Registered Remdesivir reported Repurposed drug Repurposed drugs SARS-CoV-2 scoping review searched severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe COVID-19 treat treated Treatment Trial trials
[DOI] 10.1111/bcp.14677 PMC 바로가기 [Article Type] Review